Quetiapine-induced leucopenia: Possible dosage-related phenomenon [3]

Canadian Journal of Psychiatry

Volumn 48, Issue 1, 2003, Pages 65-66

  Oluboka, Oloruntoba ^a   Haslam, David ^a   Lam, Treena ^a   Bown Demarco, Diane ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; QUETIAPINE;

ADULT; AGRANULOCYTOSIS; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; LETTER; LEUKOCYTE COUNT; LEUKOPENIA; PATIENT COMPLIANCE; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; THYROXINE BLOOD LEVEL;

EID: 0037297564     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370304800116     Document Type: Letter

References (6)

1. Arvanitis LA, Miller BG. Multiple fixed doses of "seroquel" (quetiapine) inpatients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46.
2. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG, the Seroquel Study Group. Quetiapine inpatients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-57.
3. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-73.
4. AstraZeneca. Seroquel Product Monograph 2001. Compendium of pharmaceuticals and specialities (CPS). 36th ed. Ottawa: Canadian Pharmacists Association; 2001, p 1424.
5. Anderman B, Griffith RW. Clozapine-induced agranulocytosis: a situation report up to August 1976. Eur J Clin Pharmacol 1977;11:199-201.
6. Krupp P, Barnes P. Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry 1992;160 (Suppl 17):38-40.